In the vascular business, the company is developing a next-generation Drug Eluting Stent, XIENCE Xpedition, which is expected to launch in Europe this year and in the U.S. in 2013.
FORBES: Abbott Labs Snapshot As AbbVie Begins Trading
2.
Moderate growth is expected from vascular and diagnostics division (excluding to certain royalty and supply arrangement revenues and currency impact), after the company launched various products including its next-generation Drug Eluting Stent XIENCE Xpedition and XIENCE PRIME in different parts of the world.
FORBES: Abbott Earnings Preview: What We Are Watching